Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The inter-cellular propagation of tau aggregates in several neurodegenerative diseases involves, in part, recurring cycles of extracellular tau uptake, initiation of endogenous tau aggregation, and extracellular release of at least part of this protein complex. However, human brain tau extracts from diverse tauopathies exhibit variant or "strain" specificity in inducing inter-cellular propagation in both cell and animal models. It is unclear if these distinctive properties are affected by disease-specific differences in aggregated tau conformation and structure. We have used a combined structural and cell biological approach to study if two frontotemporal dementia (FTD)-associated pathologic mutations, V337M and N279K, affect the aggregation, conformation and cellular internalization of the tau four-repeat domain (K18) fragment. In both heparin-induced and native-state aggregation experiments, each FTD variant formed soluble and fibrillar aggregates with remarkable morphological and immunological distinctions from the wild type (WT) aggregates. Exogenously applied oligomers of the FTD tau-K18 variants (V337M and N279K) were significantly more efficiently taken up by SH-SY5Y neuroblastoma cells than WT tau-K18, suggesting mutation-induced changes in cellular internalization. However, shared internalization mechanisms were observed: endocytosed oligomers were distributed in the cytoplasm and nucleus of SH-SY5Y cells and the neurites and soma of human induced pluripotent stem cell-derived neurons, where they co-localized with endogenous tau and the nuclear protein nucleolin. Altogether, evidence of conformational and aggregation differences between WT and disease-mutated tau K18 is demonstrated, which may explain their distinct cellular internalization potencies. These findings may account for critical aspects of the molecular pathogenesis of tauopathies involving WT and mutated tau.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629824PMC
http://dx.doi.org/10.3389/fncel.2019.00296DOI Listing

Publication Analysis

Top Keywords

cellular internalization
16
tau
10
internalization tau
8
inter-cellular propagation
8
endogenous tau
8
v337m n279k
8
aggregation
5
internalization
5
distinct conformations
4
conformations aggregation
4

Similar Publications

Subcellular distribution-based reference-free cancer cell discrimination with a novel AIE cationic probe.

Anal Chim Acta

November 2025

College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, China. Electronic address:

Background: The development of specific fluorescent probes for cancer cell discrimination holds significant promise for advancing cancer diagnostics. Conventionally, these probes operate by translating differences in biomarkers or microenvironmental factors into variations in whole-cell fluorescence intensity. However, this dominant, intensity-based strategy is highly susceptible to extraneous fluctuations arising from probe concentration, illumination instability and complex intracellular environment.

View Article and Find Full Text PDF

Understanding the kinetics of macrophage uptake and the metabolic fate of iron-carbohydrate complexes used for iron deficiency anemia treatment.

J Control Release

September 2025

Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen, Switzerland. Electronic address:

Iron-carbohydrate complexes (ICCs) are widely used nanomedicines to treat iron deficiency anemia, yet their intracellular fate and the mechanisms of action underlying their differences in treatment outcomes remain poorly understood. Here, we thus performed a comprehensive dynamic characterization of two structurally distinct ICCs - iron sucrose (IS) and ferric carboxymaltose (FCM) - in primary human macrophages, key cells to the iron metabolism. By employing innovative correlative microscopy techniques, elemental analysis, and in vitro pharmacokinetic profiling, we demonstrate that the uptake, intracellular trafficking, and biodegradation of ICCs depend on their physicochemical properties.

View Article and Find Full Text PDF

Proper subcellular localization of Toll-like receptors (TLRs) is essential for initiating appropriate innate immune responses against pathogens while avoiding self-reactivity. UNC93B1 is known to mediate the intracellular trafficking of nucleotide-sensing TLRs such as TLR9 which undergoes rapid internalization into endolysosomes upon reaching the cell surface. We previously demonstrated that UNC93B1 also facilitates the plasma membrane localization of TLR5, a sensor for bacterial flagellin.

View Article and Find Full Text PDF

pH-triggered Schottky heterojunctions for NIR-II-activated and tumor-specific pyroelectrodynamic and photothermal therapy.

J Colloid Interface Sci

September 2025

Institute of Biomedical Engineering, College of Medicine, Key Laboratory of Advanced Technologies of Materials, Ministry of Education, Southwest Jiaotong University, Chengdu 610031, PR China. Electronic address:

Pyroelectrodynamic therapy (PEDT) of tumors faces challenges due to its low electrocatalytic efficiency at mild temperature and the potential for off-target toxicity to healthy tissue. To overcome these issues, we have engineered pyroelectric nanoparticles (NPs) that feature a pH-triggered heterojunction structure and tumor-selective reactive oxidative species (ROS) production, faclitating synergistic PEDT and mild photothermal therapy (PTT). Herein, molybdenum trioxide (MoO) was deposited in-situ on the surface of tetragonal BaTiO (tBT) to create tBT@MO.

View Article and Find Full Text PDF

Dual-action nanotherapy: Temozolomide-loaded, anti-PD-L1 scFv-functionalized lipid nanocarriers for targeted glioblastoma therapy.

Eur J Pharm Sci

September 2025

Department of Neurology, Massachusetts General Hospital, Boston, MA, 02129, USA; Neuroscience Program, Harvard Medical School, Boston, MA, 02129, USA. Electronic address:

Glioblastoma (GBM) is a highly malignant brain tumor with limited treatment options and poor prognosis. GBM exhibits resistance to conventional therapies, including temozolomide (TMZ), radiotherapy, and immunotherapy, partly due to immunosuppressive mechanisms such as programmed death-ligand 1 (PD-L1) overexpression. To address these challenges, we developed TMZ-loaded nanostructured lipid carriers (NLCs) conjugated with anti-PD-L1 single-chain variable fragments (scFv) for dual chemo-immunotherapy.

View Article and Find Full Text PDF